CMS Says 'No' to Vagus Nerve Stimulation for Depression
In a company release, the VNS device manufacturer, Cyberonics, Inc., announced that the CMS had declined its request for approval and stated it was "very disappointed in the position taken by CMS that new evidence accumulated over the past 5 years and recently published in 4 peer-reviewed journals does not support reconsideration of the non-coverage decision."
"We believe the total body of evidence that began appearing in the scientific literature in 1998 presents compelling rationale for access to VNS therapy in a very ill subpopulation of Medicare beneficiaries," Cyberonics' president and CEO Dan Moore said in the company release.
"The company plans to work with other interested parties to continue to pursue access to this important therapeutic option for patients who could benefit from VNS Therapy, including carefully evaluating all options for appealing this decision," Moore added.
The VNS Therapy System has been approved by the US Food and Drug Administration for the treatment of refractory epilepsy and treatment-resistant depression.
Send comments and news tips to firstname.lastname@example.org.
Listed below is my email response to the above article I sent to Medscape:
Sent: Friday, May 31, 2013 2:30 AM
Subject: CMS Says 'No' to Vagus Nerve Stimulation for Depression - Caroline Cassels - May 30, 2013